Lupin secures Health Canada approval for Enbrel biosimilar – Rymti

Lupin Limited has secured approval from Health Canada for Rymti, the company’s biosimilar to Enbrel (etanercept), an inhibitor of tumour necrosis factor (TNF). Rymti is ... Read More